Vol. 6 (12) pp. 900-903 DOI: 10.21474/IJAR01/8214

VALVULOPATHIE CARDIAQUE SEVERE SECONDAIRE A LA CABERGOLINE REVERSIBLE APRES L\'ARRET DU MEDICAMENT :A PROPOS DUN CAS.

, and
  • Serviced?endocrinologie, diabetologie , maladies metaboliques et nutrition,laboratoirepcim, fmpm. Universite cadi ayad. CHUMohamed VI. Marrakech.
12 Downloads 69 Views
Crossref

Download Full Paper (PDF)

Abstract

Nous rapportons lecasd\'unepatiente de 34 ans consultant pour un ad?nomehypophysaire de 2,2 cm en contact avec le chiasmaoptique. La patiente a ?t?trait?avec 1 mg / semaine de Cabergoline (agonistedopaminergique DA) et a d?velopp?unevalvulopathietricuspidestade III qui a ensuite?t?r?versible apr?s l\'arr?t du traitementpar la Cabergoline .

Article Analytics

References

  1. Drake WM, Stiles CE, Howlett TA, et al. :?A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.?J ClinEndocrinolMetab.?2014;99(1):90?6 10.1210/jc.2013-2254
  2. Auriemma RS, Pivonello R, Perone Y, et al. :?Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.?Eur J Endocrinol.2013;169(3):359?366 10.1530/EJE-13-0231
  3. Boguszewski CL, dos Santos CM, Sakamoto KS, et al. :?A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.?Pituitary.?2012;15(1):44?49 10.1007/s11102-011-0339-7
  4. Nachtigall LB, Valassi E, Lo J, et al. :?Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.?ClinEndocrinol (Oxf).?2010;72(1):53?58 10.1111/j.1365-2265.2009.03608.x
  5. Elenkova A, Shabani R, Kalinov K, et al. :?Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.?Eur J Endocrinol.?2012;167(1):17?25 10.1530/EJE-12-0121
  6. Valassi E, Klibanski A, Biller BM:?Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.?J ClinEndocrinol Metab.2010;95(3):1025?1033 10.1210/jc.2009-2095
  7. Peralta C, Wolf E, Alber H, et al. :?Valvular heart disease in Parkinson\'s disease vs. controls: An echocardiographic study.?MovDisord.?2006;21(8):1109?1113 10.1002/mds.20887
  8. Bogazzi F, Buralli S, Manetti L, et al. :?Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.?Int J ClinPract.?2008;62(12):1864?1869 10.1111/j.1742-1241.2008.01779.x
  9. Melmed S, Casanueva FF, Hoffman AR, et al. :?Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.?J ClinEndocrinolMetab.?2011;96(2):273?288 10.1210/jc.2010-1
  10. Schade R, Andersohn F, Suissa S, et al. :?Dopamine agonists and the risk of cardiac-valve regurgitation.?N Engl J Med.?2007;356(1):29?38 10.1056/NEJMoa062222
  11. Bhattacharyya S, Schapira AH, Mikhailidis DP, et al. :?Drug-induced fibrotic valvular heart disease.?Lancet.?2009;374(9689):577?585 10.1016/S0140-6736(09)60252-X
  12. Mast ST, Jollis JG, Ryan T, et al. :?The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.?Ann Intern Med.?2001;134(4):261?266 10.7326/0003-4819-134-4-200102200-00008
  13. Pinero A, Marcos-Alberca P, Fortes J:?Cabergoline-related severe restrictive mitral regurgitation.?N Engl J Med.?2005;353(18):1976?1977 10.1056/NEJM200511033531822
  14. Zanettini R, Antonini A, Gatto G, et al. :?Valvular heart disease and the use of dopamine agonists for Parkinson\'s disease.?N Engl J Med.?2007;356(1):39?46 10.1056/NEJMoa054830
  15. Lancellotti P, Livadariu E, Markov M, et al. :?Cabergoline and the risk of valvular lesions in endocrine disease.?Eur J Endocrinol.?2008;159(1):1?5 10.1530/EJE-08-0213
  16. Droogmans S, Roosens B, Cosyns B, et al. :?Dose dependency and reversibility of serotonin-induced valvular heart disease in rats.?CardiovascToxicol.?2009;9(3):134?141 10.1007/s12012-009-9046-2
  17. Jahnichen S, Horowski R, Pertz HH:?Agonism at 5?HT2B receptors is not a class effect of the ergolines.?Eur J Pharmacol.?2005;513(3):225?228 10.1016/j.ejphar.2005.03.010
  18. Serratrice J, Disdier P, Habib G, et al. :?Fibrotic valvular heart disease subsequent to bromocriptine treatment.?Cardiol Rev.?2002;10(6):334?336
  19. Ruzicka E, Linkova H, Penicka M, et al. :?Low incidence of restrictive valvulopathy in patients with Parkinson\'s disease on moderate dose of pergolide.?J Neurol.2007;254(11):1575?1578 10.1007/s00415-007-0592-x
  20. Colao A, Galderisi M, Di Sarno A, et al. :?Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.?J ClinEndocrinolMetab.?2008;93(10):3777?3784 10.1210/jc.2007-1403
  21. Vallette S, Serri K, Rivera J, et al. :?Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.?Pituitary.?2009;12(3):153?157 10.1007/s11102-008-0134-2
  22. Tan LC, Ng KK, Au WL, et al. :?Bromocriptine use and the risk of valvular heart disease.?MovDisord.?2009;24(3):344?349 10.1002/mds.22228
  23. Van Camp G, Flamez A, Cosyns B, et al. :?Treatment of Parkinson\'s disease with pergolide and relation to restrictive valvular heart disease.?Lancet.2004;363(9416):1179?1183 10.1016/S0140-6736(04)15945-X.

How to Cite This Article

H. Moata, g. El mghari and n.el Ansari. (2018); VALVULOPATHIE CARDIAQUE SEVERE SECONDAIRE A LA CABERGOLINE REVERSIBLE APRES L\'ARRET DU MEDICAMENT :A PROPOS DUN CAS., Int. J. of Adv. Res., 6 (12), 900-903, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/8214

Corresponding Author

hanane moata
doctor
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.